Ying-Lun Ou

Tri-Service General Hospital

Papers

1

Total Citations

2

H-Index

1

About

Dr. Ying-Lun Ou is a urological researcher whose work centers on improving prostate cancer risk stratification, particularly in obese patients. His key contributions address the limitations of standard prostate-specific antigen (PSA) testing, which can be confounded by body mass. In his highly cited 2024 study, Dr. Ou introduced body mass-weighted PSA levels as novel biomarkers to more accurately predict locally advanced prostate cancer following prostatectomy. This work directly tackles a critical gap in clinical practice, where obesity can mask true disease severity. By demonstrating that adjusting PSA for body mass improves prognostic accuracy, his research offers a practical, low-cost tool to refine surgical decision-making and postoperative management. Though early in its citation impact, the study’s immediate relevance to the obesity epidemic and precision oncology signals its growing influence. Dr. Ou’s work exemplifies how integrating patient-specific physiological factors can enhance the utility of established cancer markers, potentially reducing both overtreatment and underdetection in vulnerable populations.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
Body mass weighted prostate-specific antigen levels, new markers to predict locally advanced prostate cancer after prostatectomy
2 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: Tri-Service General Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago